[HTML][HTML] Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Q Dong, H Bao, J Wang, W Shi, X Zou, J Sheng… - Frontiers in …, 2023 - frontiersin.org
In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Q Dong, H Bao, J Wang, W Shi, X Zou… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
[HTML][HTML] Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Q Dong, H Bao, J Wang, W Shi, X Zou… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Q Dong, H Bao, J Wang, W Shi, X Zou… - … Series-Liver Fibrosis …, 2024 - books.google.com
With the prevalence and development of the disease, non-alcoholic fatty liver disease
(NAFLD) has become the most general etiology of chronic liver disease worldwide. As one …
(NAFLD) has become the most general etiology of chronic liver disease worldwide. As one …
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Q Dong, H Bao, J Wang, W Shi, X Zou, J Sheng… - Frontiers in …, 2023 - europepmc.org
In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies.
Q Dong, H Bao, J Wang, W Shi, X Zou, J Sheng… - Frontiers in …, 2023 - europepmc.org
In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …